Bexson Biomedical Closes $4.8M Series A Financing To Develop Wearable Ketamine Technology
The $4.8 million raise was led by Greyhouse Partners' Noetic Psychedelic Fund. Noetic advisor Warren Wright also agreed to join Bexson’s board of directors, supporting the company in expanding its research programs to facilitate dosing and delivery technologies for a variety of therapies beyond ketamine. According to management, the funds will allow the company to develop wearable ketamine technology and an accompanying device for pain management. Unlike other companies focused on psychedelics for the treatment of mental health issues, Bexson is betting on “the neurological connectio...